Study Information
Locations
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
Liquid biopsy is a test done on a sample of blood to examine pieces of DNA from tumor cells circulating in the blood (circulating tumor DNA, ctDNA). The detection of ctDNA in blood may be used to monitor treatment response, disease recurrence, and therapy resistance.
This study seeks to provide evidence that liquid biopsy monitoring provides useful genomic information for oncologists to improve how they treat their patients. Researchers at Sutter Health are collecting serial blood samples from eligible patients with newly diagnosed metastatic melanoma or metastatic lung cancer to monitor ctDNA mutations as participants undergo treatment. All participants will have results from ctDNA testing provided to their treating physicians.
Eligibility Requirements
Patients with newly diagnosed metastatic melanoma or metastatic lung cancer.
Co-Investigator(s)
Mohammed Kashani-Sabet, M.D., Deepti Behl, MD
Recruitment Information
Contact Gregory Tranah, Ph.D., Scientific Director, CPMC Research Institute, for more information. Email Dr. Tranah at TranahG@cpmcri.org.
Related Studies
COVID-19 Impacts on Cancer Care Management, Patient Experience and Care Costs
Investigators: Cheryl Stults, Ph.D., Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D.
Stupski Serious Illness Program Evaluation
Investigator: Sylvia Sudat, PhD
Impact of COVID-19 on Cancer Care Management
Investigators: Su-Ying Liang, Ph.D., Monique de Bruin, M.D., MPH
Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related Conditions
Investigator: Su-Ying Liang, Ph.D.
Improving Cancer Care
Investigator: Su-Ying Liang, Ph.D.
Multilevel Study of Lung Cancer Screening Guidelines Implementation (MUST)
Investigator: Jiang Li, Ph.D., MPH
Implementing Universal Lynch Syndrome Screening Across Multiple Healthcare Systems: Identifying Strategies to Facilitate and Maintain Programs in Different Organizations Contexts
Investigators: External PI, Principal Investigator, Su-Ying Liang, Ph.D., Monique de Bruin, M.D., MPH
Lung Cancer in Never Smokers: Incidence, Risk Factors and Molecular Characteristics in Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Women
Investigators: Su-Ying Liang, Ph.D., External PI, Principal Investigator
Using Electronic Health Records to Understand Pathways of Breast Cancer Screening and Care
Breast Cancer Chemoprevention in Primary Care at Geisinger
Investigators: External PI, Principal Investigator, Xiaowei (Sherry) Yan, PhD, MS